Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $4.70, but opened at $4.95. Autolus Therapeutics shares last traded at $4.68, with a volume of 58,237 shares.
Autolus Therapeutics Stock Up 2.1 %
The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -4.00 and a beta of 2.04. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $3.92 and a 200-day moving average of $4.14.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth $43,000. Daiwa Securities Group Inc. grew its stake in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new position in Autolus Therapeutics in the third quarter valued at about $91,000. Bayesian Capital Management LP purchased a new position in Autolus Therapeutics in the first quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Autolus Therapeutics in the first quarter worth about $108,000. Institutional investors and hedge funds own 72.83% of the company's stock.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Recommended Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
